Standard dose (Mayo regimen) 5-fluorouracil and low dose folinic acid: Prohibitive toxicity?

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 1, 2000, Pages 94-98

  Tomiak, Anna ^a   Vincent, Mark ^a   Kocha, Walter ^a   Taylor, Marianne ^a   Winquist, Eric ^a   Keith, Bruce ^a   Sawyer, Michael ^a   Griffeth, Shirley ^a   Whiston, Frances ^a   Stitt, Larry ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

5 Fluorouracil; Dose reduction; Mayo regimen; Toxicity

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DRUG TOLERANCE; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0034047817     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200002000-00025     Document Type: Article

References (19)

1. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-17.
2. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967-72.
3. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12:14-20.
4. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as post-operative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246-50.
5. Cunningham D, Zalcberg JR, Rath U, et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995;31A:1945-54.
6. Leichman CG, Fleming TR, Muggia FM, et al. Phase II1 study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 1995;13:1303-11.
7. de Gramont A, Bosset J-F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J Clin Oncol 1997;15:808-15.
8. Fried G, Tsalik M, Stein M, et al. 5-Fluorouracil and low dose leucovorin in metastatic colorectal cancer: a pilot study. Cancer Chemother Pharmacol 1995;35:437-40.
9. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase 1 clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
10. Zalcberg J, Cunningham D, Rath U, et al. Modulated 5FU: female gender and increasing age are associated with significantly more grade 3 or 4 leucopenia and mucositis [Abstract]. Proc Am Soc Clin Oncol 1996;15:201.
11. Vincent M, Whiston F, Tomiak A. Mini-meta-analysis of toxicity of full dose Mayo regimen (FUFA) from two randomized controlled trials (RCTs): a concern about dose [abstract]. Proc Am Soc Clin Oncol 1999;18:930.
12. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Cancer 1995;75: 11-7.
13. Weinerman B. Increased incidence of toxicity in elderly females treated with 5FU, leucovorin [Abstract]. Am Soc Clin Oncol 1996;15:225.
14. Tepper JE, O'Connell MJ, Petroni GR, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of Intergroup 0114 J Clin Oncol 1997;15:2030-9.
15. Steinberg J, Erlichman C, Gadallu T, et al. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil folinic acid. Eur J Cancer 1992;28A:1817-20.
16. Donelli MG, Zucehetti M, Munzone E, et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998;34:33-46.
17. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433-8.
18. Houyau P, Gay C, Chatelut E, et al. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst 1993;85:1602-3.
19. Etienne M-C, Guillot T, Milano G. Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy. Ann Oncol 1996;7:283-9.